当前位置: 首页 >> 检索结果
共有 130140 条符合本次的查询结果, 用时 1.6354117 秒

61. Reversing the rise of liver cancer.

作者: The Lancet.
来源: Lancet. 2025年406卷10504期665页

62. The environmental impacts of conflict.

作者: Rebecca Sers.
来源: Lancet. 2025年

63. The Partnership for Maternal, Newborn, and Child Health: 2026-30 strategy.

作者: Helen Clark.;Rajat Khosla.
来源: Lancet. 2025年406卷10503期596-597页

64. Sheldon Greenfield.

作者: Andrew Green.
来源: Lancet. 2025年406卷10501期328页

65. Chikungunya virus disease returns to Europe: a turning point for the global arboviral landscape.

作者: Alimuddin Zumla.;Francine Ntoumi.;Guiseppe Ippolito.; .
来源: Lancet. 2025年

66. Clinical Rounds: a new section to The Lancet's clinical content.

作者: Jessamy Bagenal.;Sabine Kleinert.;Jonathan Pimm.;Chloe Wilson.
来源: Lancet. 2025年406卷10502期429页

67. QFR vs FFR for intermediate coronary stenosis.

作者: Christiaan Vrints.;Felicita Andreotti.
来源: Lancet. 2025年406卷10501期335页

68. QFR vs FFR for intermediate coronary stenosis - Authors' reply.

作者: Birgitte Krogsgaard Andersen.;Javier Escaned.;Evald H Christiansen.;Niels Ramsing Holm.
来源: Lancet. 2025年406卷10501期335-336页

69. QFR vs FFR for intermediate coronary stenosis.

作者: Kazuo Komamura.;Hiroshi Miyake.;Koichi Kobayashi.;Ryoji Ishiki.;Mitsunori Iwase.
来源: Lancet. 2025年406卷10501期334页

70. QFR vs FFR for intermediate coronary stenosis.

作者: Yoshinobu Onuma.;Tsung-Ying Tsai.;Faisal Sharif.;Joanna Wykrzykowska.;Patrick W Serruys.
来源: Lancet. 2025年406卷10501期334页

71. QFR vs FFR for intermediate coronary stenosis.

作者: Qingqing Zhu.;Yongqing Cheng.;Sibo Wang.
来源: Lancet. 2025年406卷10501期333-334页

72. QFR vs FFR for intermediate coronary stenosis.

作者: Gaston A Rodriguez-Granillo.;Hector M Garcia-Garcia.;Jorge Thierer.
来源: Lancet. 2025年406卷10501期333页

73. Ligelizumab use for chronic spontaneous urticaria - Authors' reply.

作者: Ana M Giménez-Arnau.;Manmath Patekar.;Vineeth Varanasi.;Thomas Severin.
来源: Lancet. 2025年406卷10501期332-333页

74. Early-onset colorectal cancer among Indigenous populations.

作者: Gail Garvey.;Tsegaw Amare Baykeda.;Shafkat Jahan.
来源: Lancet. 2025年406卷10501期331页

75. Ligelizumab use for chronic spontaneous urticaria.

作者: Sara Osborne.;Carolynne Vo.;Shivani Thacker.;Raquel Wescott.;Jashin J Wu.
来源: Lancet. 2025年406卷10501期331-332页

76. Redefining female leadership by choosing support over rivalry.

作者: Mia Gisselbaek.;Idit Matot.;Karin Becke-Jakob.;Britta S von Ungern-Sternberg.;Joana Berger-Estilita.;Sarah Saxena.
来源: Lancet. 2025年406卷10501期330-331页

77. The costs of ratifying and implementing the Pandemic Agreement.

作者: Clare Wenham.;Rebecca Katz.
来源: Lancet. 2025年406卷10501期329-330页

78. Transformative advances in Crohn's disease management.

作者: The Lancet.
来源: Lancet. 2025年406卷10501期307页

79. Health systems in limited statehood: a new analytical lens for research and practice.

作者: Fouad M Fouad.;Ibrahim R Bou-Orm.
来源: Lancet. 2025年

80. Bipolar disorder.

作者: Balwinder Singh.;Holly A Swartz.;Alfredo B Cuellar-Barboza.;Ayal Schaffer.;Tadafumi Kato.;Annemieke Dols.;Sarah H Sperry.;Andrea B Vassilev.;Katherine E Burdick.;Mark A Frye.
来源: Lancet. 2025年
The hallmark of bipolar disorder is hypomania or mania, and the predominant phase of illness is depression. Affecting approximately 40 million individuals worldwide, bipolar disorder is associated with a substantial psychosocial, medical, and financial burden and increased mortality from suicide and other causes. Diagnosis can be challenging due to symptom overlap with attention-deficit hyperactivity disorder, major depressive disorder, psychotic spectrum disorders, and personality disorders, which often leads to a delay in diagnosis. Recent advancements in understanding disease risk and pathophysiology have identified multigene risk and possible infectious and mitochondrial causes. Treatment approaches include pharmacotherapy, psychotherapy, and lifestyle modifications, which should always be patient-centred and aligned with individual goals and priorities. Future directions for bipolar disorder care include increasing the availability of psychosocial interventions aimed at self-management, addressing treatment-resistant bipolar depression, deepening the understanding of pathophysiology, and exploring novel interventions, such as ketamine, esketamine, other rapid-acting antidepressants, and various neuromodulation approaches.
共有 130140 条符合本次的查询结果, 用时 1.6354117 秒